Stocks in Play - 9th March 2026

Today in Focus: UMAC, RLMD, XENE

Trading Services I Use in my Trading:

StockAnalysis.com - I’ve been using Stock Analysis as an affordable but reliable method of looking at New and Upcoming IPOs, Earnings Calendars and most notably KPIs (Key Performance Indicators). Stock Analysis allows you to view the KPIs for many companies with up to date metrics and segments that you can cross reference against Earnings Results. This is incredibly important when understanding what metrics move a stock. At $65 per year it’s a no brainer. They’ve given me a discount code if you use IRISHBORNINVESTOR they will give you another 10% Off.

Situational Awareness

Market Condition: Negative, VIX big gap up.

Commentary: VIX big gap up. Impressive bounce in the market off of the lows overnight. Caution still advised. No need to be taking on a lot of market linked risk here. Potential for oversold bounce day this week. VIX is the thing to watch here. If you see that fading then we are closer to a bottom. The VIX will not sustain over $35 for long but whether this will be a shakeout before a stronger market or the beginning of a larger decline is anybody’s guess.

Weekend Focus was Biotechs and Drones and that looks to be playing out today.

Upcoming Earnings:
Today AMC: FLNT, GLRE, RAIL, YALA, AMPY

Tomorrow BMO: MSGM, CDRE, ADCT

Trade Updates:

Current Positions: FSLY, DELL, INNV, SWBI, NKTR, PVLA, YOU, ROIV, CRCL, MRVL, AMPX

In Play

XENE:  Phase 3 Topline Results

Key Metrics: Industry Group: Biotechnology, Market Cap: 5.12B, Float: 80.26M, Short Interest: 6.70%, Days to Cover: 5.91, Sales Y/Y TTM: -, EPS Y/Y TTM: -44.99%, Earnings: Feb 26 AMC, Exchange: NASDAQ

Catalyst: Announced Phase 3 X-TOLE2 topline results for azetukalner, a novel KV7 potassium channel opener, in adult patients with focal onset seizures (FOS). The study met its primary endpoint in both dose arms with extraordinary statistical significance. The 25 mg dose produced a median percent change (MPC) in monthly FOS frequency of -53.2% versus -10.4% for placebo (p=0.000000000006). Strong Safety.

Large multi Year base. Has been choppy previously but clean breakout this morning. Strong setup especially in a weak market. I flagged biotechs over the weekend as a focus and XENE was on our Biotech Watchlist.

"We are very happy to announce these data for azetukalner, which exceeded expectations and, to our knowledge, show the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study." — Ian Mortimer, CEO

RLMD:  Phase II Interim Data + Private Placement

Key Metrics: Industry Group: Biotechnology, Market Cap: 474.46M, Float: 60.48M, Short Interest: 1.84%, Days to Cover: 1.61, Sales Y/Y TTM: -, EPS Y/Y TTM: 37.37%, Earnings: Nov 13 AMC, Exchange: NASDAQ

Catalyst: Relmada Therapeutics released 12-month interim Phase 2 data for NDV-01, its sustained-release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), in high-risk non-muscle invasive bladder cancer (NMIBC). The headline numbers are impressive: a 76% complete response (CR) rate at 12 months in the overall population (n=25 evaluable at 12 months; 48 dosed total). At the same time they announced a $160m Private Placement with a lot of Institutional Heavyweights taking part.

Good chart not neglected but worth noting this is an IBRX competitor that is likely a lot more legit.

These findings support the potential best-in-class profile of NDV-01" — CMO Raj S. Pruthi, MD

UMAC:  Strong Earnings and Trump Deal

Key Metrics: Industry Group: Computer Hardware, Market Cap: 684.41M, Float: 33.47M, Short Interest: 14.81%, Days to Cover: 1.53, Sales Y/Y TTM: 133.20%, EPS Y/Y TTM: -253.98%, Earnings: Mar 09 BMO, Exchange: NASDAQ

Catalyst: Revenue dramatically outpaced consensus on enterprise fulfillment ramp (+38.4%), but GAAP EPS miss (-$0.36 vs. -$0.07) is almost entirely attributable to $6.1M non-cash stock-based compensation in Q4 alone. FY2025 net loss narrowed 40% YoY. Strong Growth Guide and Guiding for Cashflow Positive in FY26.

SBC is large and this company is probably shady but who cares. They are an investor in the new Trump Drone SPAC/Reverse Merger. Good chart, High Short interest.

Delayed Reaction/Continuation Watchlist:

Monitoring: N/A

Delayed Reaction Watchlist (TradingView Link)

_{Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.}